secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2022-12-29T23:59:59+00:00
Accession:  0001140361-22-047453
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 5.02, 3.02, 3.03, 5.01, 5.03, 5.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine completes reverse merger with Gemini Therapeutics; combined entity trades as IRON
--------------------------------------------------------------------------------

- Merger closed Dec 29, 2022; Disc becomes wholly owned sub; combined company renamed Disc Medicine, Inc., trading on Nasdaq as 'IRON' from Dec 30.
- Issued ~12.53M shares to Disc stockholders at 0.1096 exchange ratio; ~16.92M shares outstanding post-merger with 1-for-10 reverse split.
- Board reconstituted with nine members; Donald Nicholson appointed Executive Chairman; John Quisel (former Disc CEO) remains CEO.
- Pre-merger Gemini stockholders receive CVRs entitling them to contingent payments from future sale of Gemini legacy assets; no guarantee of payout.
- Registration rights agreement grants Disc investors shelf registration for resale; Roche issued 482,313 shares as part of pre-closing license addendum.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000114036122047453/0001140361-22-047453-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000114036122047453/brhc10045896_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-22-047453

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer